

Contents

2 Suzuken Group Business Activities

3 Financial Highlights

4 To Our Stakeholders

7 Interview with the President and
Chief Executive Officer

14 Corporate Framework

25 **Financial Section**

61 Independent Auditors' Report

62 Stock Information

64 List of Subsidiaries

65 Corporate Data


Suzuken Group Business Activities

In taking a broad overview of the medical treatment and healthcare domain, a variety of processes are apparent in each sector. For example, before newly developed pharmaceuticals are prescribed to patients, there is an upstream process centered on pharmaceutical companies of discovering a chemical compound with pharmaceutical potential, developing and manufacturing a new drug, distributing it and prescribing it to patients. This is then followed by a mid-stream process involving diagnosis, treatment, and prescription of the product at healthcare facilities and dispensing pharmacies.

Finally, this is completed by a downstream process that broadly encompasses activities such as disease prevention and health restoration, maintenance, and improvement that focuses on human health.

Here at the Suzuken Group, our business activities serve as a pipeline between manufacturers and medical institutions, centered around the pharmaceutical distribution business. In the medical treatment and healthcare domain, we look to create new value through the establishment of a medical distribution platform aiming to be the best partner to bring a smile to everyone.

Pharmaceutical Distribution Business



Sales ratio

Main Companies


SUZUKEN Co., LTD., SANKI CORPORATION, ASTIS Co., LTD., SHOYAKU Co., LTD., SUZUKEN OKINAWA YAKUHIN Co., LTD., NAKANO YAKUHIN Co., LTD., SUZUKEN IWATE Co., LTD.

Business Outline

The Suzuken Group is at the forefront of the industry in having developed an extensive nationwide sales network across Japan, allowing us to readily collate

new cases on a national scale and create an infrastructure capable of processing frontline medical information of value before sharing this with healthcare facilities and dispensing pharmacies. In addition to our strengthening delivery capacity, we have established a structure that enhances the Group's corporate value in society centered on satisfying our patients and customers. Our adoption of the industry's first traceability system reflects our commitment to the development of a reliable logistics system.

Pharmaceutical Manufacturing Business



Sales ratio

Main Company


SANWA KAGAKU KENKYUSHO Co., LTD.

Business Outline

SANWA KAGAKU KENKYUSHO Co., LTD., a consolidated subsidiary of the Suzuken Group, acts as a best partner for diabetes sufferers

in its unstinting approach to the field of diabetes treatment, from research and development to manufacture and sales. This includes the development of medical pharmaceuticals such as *Seibule* – an agent for postprandial hyperglycemia, diagnostic reagents, and foods for medical use.

Healthcare-related Services



Sales ratio

Main Companies

Healthcare-related services:
LIFE MEDICOM Co., LTD., SANKI-CLINICAL LINK Co., LTD.
Manufacture of diagnostic equipment:
KENZMEDICO Co., LTD.
Dispensing pharmacy:
PFERCO Co., LTD.
Other:
LIFE SUPPORT Co., LTD.

Business Outline

The Suzuken Group provides a diverse range of services in the healthcare field. This segment of our business operations includes the manufacture of diagnostic equipment such as electrocardiographs and blood pressure meters, operation of dispensing pharmacies, publications in medical and healthcare fields, and dispatch of clinical research coordinators.

Note: This data includes intersegment transactions.

Financial Highlights

Suzuken Co., Ltd. and Subsidiaries
Years ended March 31

	2009	2008	2007	2006	2005	2004	2009
<i>Millions of Yen except per share data Thousands of U.S. Dollars except per share data</i>							
For the year:							
Net sales	¥ 1,641,332	¥ 1,586,596	¥ 1,454,842	¥ 1,388,695	¥ 1,330,983	¥ 1,194,024	\$ 16,748,286
Gross profit	162,065	164,040	148,362	140,525	129,072	125,120	1,653,724
Selling, general and administrative expenses	147,384	140,789	129,951	123,721	116,711	105,413	1,503,918
Operating income	14,681	23,251	18,411	16,804	12,361	19,707	149,806
Net income	7,072	21,327	17,702	17,184	12,576	17,308	72,163
Per share data:							
						<i>Yen</i>	<i>U.S. Dollars</i>
Net income (EPS)							
Basic	77.10	230.49	191.72	187.42	135.72	193.08	0.787
Diluted	—	—	—	—	135.46	189.98	—
Cash dividends	62.00	50.00	42.00	36.00	30.00	26.00	0.633
At year-end:							
Total assets	828,516	822,853	857,516	739,871	758,232	692,365	8,454,245
Total equity	270,856	274,357	271,229	240,146	223,979	213,539	2,763,837
Ratios:							
Return on assets (ROA)(%)	0.9	2.5	2.2	2.3	1.7	2.6	
Return on equity (ROE)(%)	2.6	7.9	7.0	7.4	5.7	8.6	
Dividend payout ratio(%)	80.4	21.7	21.9	19.2	22.1	11.2	

Notes:

- 1 U.S. dollar amounts are provided solely for the reader's convenience and use the exchange rate of ¥98 to the U.S. dollar prevailing on March 31, 2009.
- 2 Net income per share is calculated using the average number of shares outstanding during each fiscal year, net of the average treasury stock during each fiscal year.
- 3 Per share data in prior years has been adjusted to reflect the 1.2-for-1 stock split conducted on March 31, 2004 (stock distribution date: May 19, 2004).

